Cargando…

Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia

SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest t...

Descripción completa

Detalles Bibliográficos
Autores principales: Geilswijk, Marianne, Andersen, Lise Lotte, Frost, Morten, Brusgaard, Klaus, Beck-Nielsen, Henning, Frederiksen, Anja Lisbeth, Jensen, Dorte Møller
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404468/
https://www.ncbi.nlm.nih.gov/pubmed/28458896
http://dx.doi.org/10.1530/EDM-16-0126
_version_ 1783231603601833984
author Geilswijk, Marianne
Andersen, Lise Lotte
Frost, Morten
Brusgaard, Klaus
Beck-Nielsen, Henning
Frederiksen, Anja Lisbeth
Jensen, Dorte Møller
author_facet Geilswijk, Marianne
Andersen, Lise Lotte
Frost, Morten
Brusgaard, Klaus
Beck-Nielsen, Henning
Frederiksen, Anja Lisbeth
Jensen, Dorte Møller
author_sort Geilswijk, Marianne
collection PubMed
description SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy. LEARNING POINTS: Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia. Hypoglycemia during pregnancy may have serious health implications for mother and fetus. Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only.
format Online
Article
Text
id pubmed-5404468
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-54044682017-04-28 Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia Geilswijk, Marianne Andersen, Lise Lotte Frost, Morten Brusgaard, Klaus Beck-Nielsen, Henning Frederiksen, Anja Lisbeth Jensen, Dorte Møller Endocrinol Diabetes Metab Case Rep Error in Diagnosis/Pitfalls and Caveats SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy. LEARNING POINTS: Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia. Hypoglycemia during pregnancy may have serious health implications for mother and fetus. Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only. Bioscientifica Ltd 2017-02-15 /pmc/articles/PMC5404468/ /pubmed/28458896 http://dx.doi.org/10.1530/EDM-16-0126 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Error in Diagnosis/Pitfalls and Caveats
Geilswijk, Marianne
Andersen, Lise Lotte
Frost, Morten
Brusgaard, Klaus
Beck-Nielsen, Henning
Frederiksen, Anja Lisbeth
Jensen, Dorte Møller
Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
title Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
title_full Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
title_fullStr Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
title_full_unstemmed Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
title_short Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
title_sort octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
topic Error in Diagnosis/Pitfalls and Caveats
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404468/
https://www.ncbi.nlm.nih.gov/pubmed/28458896
http://dx.doi.org/10.1530/EDM-16-0126
work_keys_str_mv AT geilswijkmarianne octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia
AT andersenliselotte octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia
AT frostmorten octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia
AT brusgaardklaus octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia
AT becknielsenhenning octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia
AT frederiksenanjalisbeth octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia
AT jensendortemøller octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia